If fatigue persists beyond the initial adjustment period (typically a few weeks), your healthcare provider might want to investigate other potential causes
Inhibitors of DPP-4, such as sitagliptin, vildagliptin and linagliptin, inhibit DPP-4, resulting in an increase of incretin and GLP-1 secretion (Figure 1), leading to an improvement in plasma glucose control without inducing hypoglycemia or increasing the body weight.69 Both types of drugs are barely metabolized in the liver and are excreted unchanged by the kidney;70 thus, they seem to be safe in cirrhotic patients.71 Unlike the old antidiabetic drugs, their pharmacodynamic characteristics have been assessed in patients with varying degrees of hepatic impairment and their safety has been assessed in studies comprising large number of individuals
Want more support for your GLP-1 journey
About 100 mg (dry weight) of immobilization carriers were collected and weighed in a 15 mL tube, N,N -dimethyl-4-aminopyridine (DMAP) (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) and N,N' -disuccinimidyl carbonate (DSC) (Tokyo Chemical Industry, Tokyo, Japan) were weighed to 1.51- and 3.16-times the weight of the immobilization carrier, respectively
BMC Public Health 18 , 605 (2018)
overall specificity 0.84), the RCM is more specific (overall specificity of RCM 0.89) and sensitive (overall sensitivity of RCM 0.93) [35]
